Published in Breast Dis on January 01, 2000
Prognostic molecular markers in early breast cancer. Breast Cancer Res (2004) 1.56
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin Med Insights Oncol (2010) 1.13
Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. BMC Cancer (2009) 0.88
Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells. Cancer Cell Int (2013) 0.86
The role of Herceptin in early breast cancer. Int Semin Surg Oncol (2008) 0.75
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin. Molecules (2017) 0.75
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature (1986) 7.90
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (1999) 6.97
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell (1999) 6.79
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry (1987) 3.94
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry (1987) 3.20
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 3.12
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem (2000) 3.06
Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem (1983) 2.94
The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature (1998) 2.86
Expression of epidermal growth factor receptors in human brain tumors. Cancer Res (1984) 2.83
Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A (1996) 2.66
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell (1992) 2.62
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol (2000) 2.47
The avian beta-adrenergic receptor: primary structure and membrane topology. Proc Natl Acad Sci U S A (1986) 2.45
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 2.33
Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron (1997) 2.33
A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol (1991) 2.27
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development (1991) 2.16
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett (2001) 2.15
The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem (1999) 2.13
Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol (2008) 2.12
Regulation of cell proliferation by epidermal growth factor. CRC Crit Rev Biochem (1983) 2.09
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res (2000) 2.07
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron (1995) 2.02
Neu and its ligands: from an oncogene to neural factors. Bioessays (1993) 2.00
Developmental expression of c-kit, a proto-oncogene encoded by the W locus. Development (1990) 1.99
The basic biology of HER2. Ann Oncol (2001) 1.97
Epidermal growth factor induces electrically silent Na+ influx in human fibroblasts. J Biol Chem (1982) 1.96
Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J (1997) 1.96
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene (2001) 1.95
Trastuzumab: triumphs and tribulations. Oncogene (2007) 1.94
A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. EMBO J (1992) 1.93
Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc Natl Acad Sci U S A (1981) 1.87
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem (1998) 1.81
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry (1990) 1.81
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene (2007) 1.79
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J (1993) 1.74
Rotational diffusion of epidermal growth factor complexed to cell surface receptors reflects rapid microaggregation and endocytosis of occupied receptors. Proc Natl Acad Sci U S A (1981) 1.72
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene (1997) 1.64
Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol (1995) 1.63
Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem (1998) 1.62
Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies. J Biol Chem (1985) 1.61
c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene (2007) 1.59
Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J (1997) 1.58
Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. J Biol Chem (2000) 1.54
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta (1998) 1.51
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell (1992) 1.50
Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem (2001) 1.50
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J (1998) 1.49
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene (1996) 1.48
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol (2011) 1.45
An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem (1996) 1.43
Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene (1998) 1.40
Poliovirus protein 3A inhibits tumor necrosis factor (TNF)-induced apoptosis by eliminating the TNF receptor from the cell surface. J Virol (2001) 1.39
A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J (1991) 1.39
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem (1996) 1.38
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A (2008) 1.36
Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene (2001) 1.36
Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene (2000) 1.35
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene (1999) 1.34
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J (1991) 1.33
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A (1995) 1.32
Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex. J Biol Chem (2000) 1.31
EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene (2010) 1.30
KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene (1993) 1.30
p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29
ERG30, a VAP-33-related protein, functions in protein transport mediated by COPI vesicles. J Cell Biol (1999) 1.29
Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proc Natl Acad Sci U S A (1993) 1.28
Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res (1993) 1.27
Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. J Biol Chem (1996) 1.24
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res (1992) 1.24
9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene (2009) 1.24
p53 modulation of anchorage independent growth and experimental metastasis. Oncogene (1996) 1.23
Forward genetics in mammalian cells: functional approaches to gene discovery. Hum Mol Genet (1999) 1.22
ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neoplasia (1997) 1.20
Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. J Biol Chem (1992) 1.20
Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene (2008) 1.20
Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncog (1994) 1.20
p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol (1998) 1.19
Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases. J Biol Chem (1995) 1.19
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene (2007) 1.18
The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell (1995) 1.17
Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. J Biol Chem (1995) 1.17
Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain. Proc Natl Acad Sci U S A (1998) 1.17
The murine flg gene encodes a receptor for fibroblast growth factor. Oncogene (1990) 1.17